ERBB2 and breast cancer: noted that the intrinsic subtype distribution in HER2-low/HR+ BC more closely resembles HER2-null/HR+ than HER2-low/TNBC, suggesting that the biological differences are primarily driven by HR expression rather than HER2-low status (21).